Paramethasone

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic.

Rute Eliminasi

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Interaksi Obat

1246 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Paramethasone.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paramethasone.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Paramethasone.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Paramethasone.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paramethasone.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Paramethasone.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Paramethasone.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paramethasone.
Pegaspargase	The serum concentration of Paramethasone can be increased when it is combined with Pegaspargase.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paramethasone.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paramethasone.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Paramethasone.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Paramethasone.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Paramethasone.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paramethasone.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Paramethasone.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paramethasone.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Paramethasone.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Paramethasone.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paramethasone.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paramethasone.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Paramethasone.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paramethasone.
Cladribine	Paramethasone may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Paramethasone.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Paramethasone.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Paramethasone.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Paramethasone.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Paramethasone.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Paramethasone.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Paramethasone.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Paramethasone.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Paramethasone.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Paramethasone.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Paramethasone.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Paramethasone.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Paramethasone.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Paramethasone.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Paramethasone.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Paramethasone.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Paramethasone.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Paramethasone.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paramethasone.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Paramethasone.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Paramethasone.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Paramethasone.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Paramethasone.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Paramethasone.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Paramethasone.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Paramethasone.
Tretinoin	The metabolism of Tretinoin can be increased when combined with Paramethasone.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Paramethasone.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Paramethasone.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Paramethasone.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Paramethasone.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Paramethasone.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Paramethasone.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Paramethasone.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Paramethasone.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Paramethasone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Paramethasone.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Paramethasone.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Paramethasone.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Paramethasone.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Paramethasone.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Paramethasone.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Paramethasone.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Paramethasone.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Paramethasone.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Paramethasone.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Paramethasone.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Paramethasone.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Paramethasone.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Paramethasone.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Paramethasone.
Stepronin	The risk or severity of adverse effects can be increased when Paramethasone is combined with Stepronin.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Paramethasone is combined with Hydroxychloroquine.
Castanospermine	The risk or severity of adverse effects can be increased when Paramethasone is combined with Castanospermine.
Vorinostat	The risk or severity of adverse effects can be increased when Paramethasone is combined with Vorinostat.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Paramethasone is combined with 2-Methoxyethanol.
Brequinar	The risk or severity of adverse effects can be increased when Paramethasone is combined with Brequinar.
Pirfenidone	The risk or severity of adverse effects can be increased when Paramethasone is combined with Pirfenidone.
Interferon alfa	The risk or severity of adverse effects can be increased when Paramethasone is combined with Interferon alfa.
Glatiramer	The risk or severity of adverse effects can be increased when Paramethasone is combined with Glatiramer.
Briakinumab	The risk or severity of adverse effects can be increased when Paramethasone is combined with Briakinumab.
Human interferon omega-1	The risk or severity of adverse effects can be increased when Paramethasone is combined with Human interferon omega-1.
Mepolizumab	The risk or severity of adverse effects can be increased when Paramethasone is combined with Mepolizumab.
Abetimus	The risk or severity of adverse effects can be increased when Paramethasone is combined with Abetimus.
Belatacept	The risk or severity of adverse effects can be increased when Paramethasone is combined with Belatacept.
Bendamustine	The risk or severity of adverse effects can be increased when Paramethasone is combined with Bendamustine.
Pralatrexate	The risk or severity of adverse effects can be increased when Paramethasone is combined with Pralatrexate.
Wortmannin	The risk or severity of adverse effects can be increased when Paramethasone is combined with Wortmannin.
Eribulin	The risk or severity of adverse effects can be increased when Paramethasone is combined with Eribulin.
Belimumab	The risk or severity of adverse effects can be increased when Paramethasone is combined with Belimumab.
Teriflunomide	The risk or severity of adverse effects can be increased when Paramethasone is combined with Teriflunomide.
Carfilzomib	The risk or severity of adverse effects can be increased when Paramethasone is combined with Carfilzomib.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Paramethasone is combined with Dimethyl fumarate.
Obinutuzumab	The risk or severity of adverse effects can be increased when Paramethasone is combined with Obinutuzumab.
Vedolizumab	The risk or severity of adverse effects can be increased when Paramethasone is combined with Vedolizumab.

Target Protein

Corticosteroid-binding globulin SERPINA6

Glucocorticoid receptor NR3C1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 1

International Brands

Dillar

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Peringatan Keamanan

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual